Clinical trial · Interventional
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) NSCLC. Randomized Phase II Study
NCT00198367CI-TRIAL-00038812completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery followed by chemotherapy (CT) and/or radiotherapy (RT) are insufficient. The neoadjuvant approach was tested, in randomized tests of exclusive CT, or in noncomparative tests of RT-CT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin-Taxol-Radiotherapy | Drug | — | UNRESOLVED |
| Cisplatin-Gemzar | Drug | — | UNRESOLVED |
| Cisplatin-Navelbine-Radiotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cisplatin-Gemzar
- description
- Cisplatin-Gemzar
- interventionNames
- Drug: Cisplatin-Gemzar
- type
- EXPERIMENTAL
- label
- Cisplatin-Navelbine-Radiotherapy
- description
- Cisplatin-Navelbine-Radiotherapy
- interventionNames
- Drug: Cisplatin-Navelbine-Radiotherapy
- type
- EXPERIMENTAL
- label
- Carboplatin-Taxol-Radiotherapy
- description
- Carboplatin-Taxol-Radiotherapy
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Operable and resectable stage IIIA (T1-3, N2) NSCLC * World Health Organization (WHO) performance status of 1 or less Exclusion Criteria: * Severe cardiac, respiratory, renal or hepatic failure
References
Publications (1)
- RESULTGirard N, Mornex F, Douillard JY, Bossard N, Quoix E, Beckendorf V, Grunenwald D, Amour E, Milleron B. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer. 2010 Jul;69(1):86-93. doi: 10.1016/j.lungcan.2009.10.003. Epub 2009 Oct 29. PMID 19879013